Le Lézard

Communiqués de presse par sujet : Essais cliniques / Découvertes médicales

1 2 3 4 5 6 7 8 9 10 11

10 décembre 2018

08:30
Johnson & Johnson Medical Devices Companies* today announced that its CERENOVUS business has launched the single largest global registry, the EXCELLENT Registry, to collect and analyze stroke-inducing blood clots removed from the brain with its...

08:11
Long-term outcomes data from a large population-based study1, presented at the 2018 San Antonio Breast Cancer Symposium® (SABCS), further support the utility of the Oncotype DX Breast Recurrence Score® test to optimise chemotherapy recommendations in...

08:00
ZygoFix Ltd. ("ZygoFix"), a portfolio company of The Trendlines Group Ltd. ("Trendlines") (SGX: 42T) , announced the successful start of a first In human clinical study for its zLOCK spinal facet joint fixation system. The clinical study comprised...

07:45
Windtree Therapeutics, Inc. today announced that data from the AEROSURF® phase 2 clinical program in premature infants with respiratory distress syndrome (RDS) was presented at the 2018 Hot Topics in Neonatology Annual Meeting (2018 Hot Topics) held...

07:00
Vanda Pharmaceuticals Inc. (Vanda) today announced that HETLIOZ® (tasimelteon) improved sleep quality and increased sleep duration in patients with Smith-Magenis Syndrome (SMS) in a pivotal placebo controlled clinical study. "We are extremely...

03:00
Fever and pain in children can lead to lost or disrupted sleep, anxiety among the family and days of nursery, school or work missed due to illness1   Peak level flu season occurs between December and March each year2  New research has highlighted...

03:00
Biohaven Pharmaceutical Holding Company Ltd. today announced initial positive results from its ongoing long-term, open-label safety study of its oral calcitonin gene-related peptide (CGRP) receptor antagonist, rimegepant, for the acute treatment of...

02:00
Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, today announces that it has secured an undisclosed amount of funding from the Bill & Melinda Gates Foundation. The funds will be used to support the Company's...


8 décembre 2018

08:05
Novartis today announced data from subgroup analyses of the three pivotal Phase III MONALEESA trials showing that Kisqali® (ribociclib) plus endocrine therapy extended progression-free survival (PFS) compared to endocrine therapy alone, regardless of...


7 décembre 2018

17:58
Virtual Caregiving is set to enter both the healthcare industry and patient home settings. In January 2019, G60 Trauma (G60Trauma.org) will begin testing Addison Care, the world's first, comprehensive virtual caregiving system to provide real time,...

11:47
Pain after surgery can be effectively managed with minimal or no opioids, according to research conducted at Roswell Park Comprehensive Cancer Center and published today in JAMA Network Open. The publication presents the findings of a two-year pilot...

09:39
Cantargia AB (publ) today announces that all patients in the phase I part of the CANFOUR clinical trial have completed the formal safety evaluation phase of the trial. No dose limiting toxicities (DLTs) were reported at the highest dose level...

09:03
Eisai announced today that the first investigational drug candidate from their drug discovery collaboration with University College London (UCL) is to enter Phase I clinical trials for Alzheimer's disease (AD) in early 2019. The candidate, known as...

09:00
Following a series of successful initiatives in Germany and Switzerland, Malong Technologies' co-founder and chief executive officer Dr. Dinglong Huang returned home last week with fresh perspectives on the potential of artificial intelligence, and...

09:00
GREAT NECK, N.Y., Dec. 7, 2018 /PRNewswire-PRWeb/ -- Ever more effective therapies for drug addiction ? a life-threatening brain disorder ? may be on the horizon as scientists, physicians and commercial enterprises partner to respond to the national...

08:37
HealthTrackRx®, a clinical solutions company that assists healthcare providers with monitoring patients on prescription opioids, has now enrolled more than 30,000 patients in their GuideMed® program. In addition, early program data shows an average...

08:30
Agendia, Inc., a world leader in precision oncology, announced today findings from two key studies presented at the 2018 San Antonio Breast Cancer Symposium (SABCS) this week, reinforcing the utility and benefits of its MammaPrint® 70-Gene Breast...

08:30
Laboratory for Advanced Medicine (LAM), a commercial-stage medical technology company focused on developing innovative technologies for the early diagnosis of cancers, today announced new data at the San Antonio Breast Cancer Symposium validating...

08:00
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., chief executive officer, will present at the 2018 Antibody Engineering & Therapeutics Meeting. Dr. Johnson's presentation will...

01:00
Treatment with recombinant therapy RUCONEST® and plasma-derived C1 treatments requires significantly less re-dosing than icatibant (Firazyr®) to resolve HAE attacks  Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM)...


6 décembre 2018

14:12
Fimbrion Therapeutics, Inc. a annoncé que, dans le cadre de recherches menées en commun avec GSK, ses chercheurs ont identifié un candidat au développement sous forme de petite molécule à administrer par voie orale pour le traitement et la prévention...

14:00
Prelude Corporation (PreludeDx), a leader in molecular diagnostics and personalized medicine for early stage breast cancer, announced today its compelling data from research on stage 1 breast cancer patients presented at the 2018 San Antonio Breast...

13:57
EmoCellix se consacrera à la commercialisation d'une solution complète destinée au diagnostic cytomoléculaire des anomalies de l'hémostase  L'entreprise française Emosis et Accellix ont annoncé aujourd'hui qu'elles ont signé une lettre d'intention...

13:32
Results from a new clinical trial may shed new light on hypophosphatemia, a condition caused by a drop in phosphate levels in the blood that has emerged as a common side effect of a widely used intravenous iron treatment for iron deficiency anemia....

10:35
Novartis today announced additional analysis from the global Phase III SOLAR-1 trial investigating the alpha-specific PI3K inhibitor BYL719 (alpelisib) in combination with fulvestrant in men and postmenopausal women with PIK3CA mutated hormone...

09:00
Fimbrion Therapeutics, Inc. announced that under its joint research collaboration with GSK, researchers have identified an orally available, small molecule development candidate for the treatment and prevention of urinary tract infections (UTIs)....

08:58
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced it will conduct a study to identify and measure specific biomarkers in people with amyotrophic lateral sclerosis (ALS). The findings may assist researchers and clinicians in starting the...

08:49
Aujourd'hui, le laboratoire pharmaceutique suisse Berlin Cures Holding AG a annoncé la création d'un comité directeur réunissant des cardiologues renommés qui s'attacheront à fournir des informations d'experts pendant la conception et la mise en...

08:45
Sensus Healthcare, Inc. , a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), announced today positive results of a multicenter...

08:39
Leviticus Cardio, inventors of the versatile transcutaneous Coplanar Energy Transfer (CET) system used with implanted left ventricular assist devices (LVADs), announces the successful completion of a 180-day preclinical chronic animal study to...

08:03
Natera, Inc. , a leader in non-invasive genetic testing and the analysis of cell-free DNA, presented data from two studies this week at the 2018 San Antonio Breast Cancer Symposium (SABCS), demonstrating the ability of its Signateratm RUO...

08:00
Inhibrx, Inc. (Inhibrx), a clinical-stage biotechnology company with a broad pipeline of biotherapeutics in development, announced today the administration of the first dose of INBRX-109 in a Phase 1 dose-escalation clinical study. INBRX-109 is a...

07:30
Accuray Incorporated announced today that the new release of its Accuray Precision® Treatment Planning System (TPS) with the CyberKnife® VOLOtm Optimizer will enable CyberKnife System customers to significantly improve operational efficiency by...

07:00
BioLineRx Ltd. , a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will host an investor breakfast meeting on Tuesday, December 11, 2018 at the Convene Conference Center near Grand Central...

07:00
Marker Therapeutics, Inc. , a clinical-stage immuno-oncology company, today announced that its President and CEO, Peter L. Hoang, will present a corporate overview at the upcoming Tumor Targeted Lymphocytes Summit on Wednesday, December 12, 2018....

07:00
Intec Pharma Ltd. ("Intec" or "the Company") today announces that the Accordion Pilltm developed for a proprietary Novartis compound is continuing into a clinical PK study under the previously announced Feasibility and Option agreement with Novartis...

07:00
Inari Medical, Inc. announced today the enrollment of the first patient in the FlowTriever All-Comer Registry for Patient Safety and Hemodynamics ("FLASH") using the FlowTriever® System for the treatment of pulmonary embolism (PE). ...

06:45
Impel NeuroPharma ("Impel" or the "Company"), a Seattle-based, privately-held biotechnology company focused on developing therapies for the treatment of central nervous system ("CNS") disorders with unmet medical needs, today announced that it has...

06:34
EmoCellix will focus on marketing a complete solution for hemostasis cytomolecular diagnostics  The French company Emosis and Accellix today announced that they have signed a letter of intent to form a joint venture (JV) to be equally owned by...

05:00
Tychan, a clinical-stage biotechnology company based in Singapore, announced today that its first-in-class candidate drug for the treatment of Yellow Fever received investigatory new drug (IND) regulatory approval from Health Sciences Authority (HSA)...

02:00
Swiss drug developer Berlin Cures Holding AG today announced the establishment of a steering committee of renowned cardiologists focused on ensuring expert input during the design and implementation of the Phase 2 study of BC 007 for the treatment of...


5 décembre 2018

18:00
- Updated efficacy and safety results presented from ongoing phase 1/2 study with U3-1402, an investigational and potential first-in-class HER3-targeting antibody drug conjugate (ADC), in patients with heavily pretreated HER3-positive metastatic...

16:01
AbbVie , a research-based global biopharmaceutical company, today announced the decision to stop enrollment for the TAHOE trial, a Phase 3 study evaluating Rovalpituzumab Tesirine (Rova-T) as a second-line therapy for advanced small-cell lung cancer...

15:33
Children's Hospital of Philadelphia (CHOP) celebrates a pivotal moment in medicine: approval by the European Commission (EC) of LUXTURNA® (voretigene neparvovec), the first and only gene therapy for patients with an inherited retinal disease, last...

15:30
Seqirus, a global leader in influenza prevention, today presented a new real-world evidence analysis at the Canadian Immunization Conference (CIC) in Ottawa, Ontario, indicating that its cell-based quadrivalent influenza vaccine (QIVc) was 36.2...

15:30
Seqirus, un chef de file mondial de la prévention de l'influenza (grippe), a présenté aujourd'hui une nouvelle analyse des données probantes à la Conférence canadienne sur l'immunisation (CCI) à Ottawa, en Ontario, indiquant que son vaccin...

13:15
Columbia scientists have identified a brain region that helps tell an animal when to attack an intruder and when to accept it into its home. This brain area, called CA2, is part of the hippocampus, a larger brain structure known to be critical for...

10:44
FX Shoulder USA, Inc. will begin in December 2018 the FDA approved Investigational Device Exemption (IDE) clinical study of the Easytech Reversed stemless, a shoulder prosthesis, with its first implantation scheduled for December.      (Logo:...

09:43
La mise en place par apposition du treillis chirurgical synthétique et entièrement résorbable TIGR®Matrix (de l'entreprise Novus Scientific AB, Uppsala -- Suède) pour prévenir des éventrations (hernies incisionnelles) chez les patients atteints de...

09:06
Vast Therapeutics, Inc. (Vast) announced today that it has completed its Series A financing with a single investor, Shionogi & Co., Ltd. of Japan. The investment provides Vast with funding to advance their novel nitric oxide powder platform through...

1 2 3 4 5 6 7 8 9 10 11